Elicio Therapeutics Announces Appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and Promotion of Dr. Peter DeMuth to Chief Scientific Officer
May 12, 2022 08:00 ET
|
Elicio Therapeutics
BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases,...
Elicio Therapeutics Presents Preclinical Data on the AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy for Solid Tumors at the 2022 Keystone Symposia: Emerging Cellular Therapies
April 29, 2022 14:00 ET
|
Elicio Therapeutics
Data shows that AMP-vaccination significantly enhanced TCR-T cell anti-tumor response while also inducing epitope spread among the endogenous T cell population, leading to durable cures of solid...
Elicio Therapeutics Presents Updated Preclinical Data at Vaccines Summit Boston 2022 on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine, Demonstrating It Induces Potent Cross-Reactive Cellular and Humoral Immunity to SARS-CoV-2
March 29, 2022 14:00 ET
|
Elicio Therapeutics
ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primatesPrime-boost administration of...
Elicio Therapeutics Presents Preclinical Data on its Amphiphile-CpG Adjuvant at the STING & TLR-Targeting Therapies Summit 2022 Digital Event
March 23, 2022 15:30 ET
|
Elicio Therapeutics
AMP-CpG efficiently targets the lymph nodes to promote potent and comprehensive innate immune activation resulting in enhanced T and B cell responses with improved functionality and persistence ...
Elicio Therapeutics Moves into Boston’s Seaport District and Provides Update on Programs
March 15, 2022 08:00 ET
|
Elicio Therapeutics
The Company has moved from Cambridge, MA to a new, larger space in the Seaport District, Boston’s growing biotech hubEnrollment continues for the multicenter Phase 1 AMPLIFY-201 study of the lead...
Elicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Immunotherapy of Cancer Annual Meeting
November 12, 2021 07:00 ET
|
Elicio Therapeutics
Data showed Amphiphile (AMP) boosting significantly enhanced TCR-T cell anti-tumor efficacy and led to durable responses against solid tumors in an established, syngeneic tumor modelAMP boosting of...
Elicio Therapeutics Announces First Patient Dosed in the ELI-002 (AMPLIFY-201) study in KRAS-Driven Cancers
October 06, 2021 08:00 ET
|
Elicio Therapeutics
The first patient was dosed at MD Anderson as part of a multicenter clinical trial to evaluate the safety and efficacy of ELI-002, an investigational lymph node-targeted therapeutic vaccine, in...
Elicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
September 22, 2021 15:22 ET
|
Elicio Therapeutics
ELI-005, containing the Amphiphile vaccine adjuvant AMP-CpG, induced >25-fold higher antigen-specific T cells in the peripheral blood and exhibited potent killing of antigen-positive targets in...
Elicio Therapeutics Announces Virtual Presentation of Data on its Amphiphile-CpG Adjuvant at the Vaccines Summit 2021
September 17, 2021 11:35 ET
|
Elicio Therapeutics
CAMBRIDGE Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other...
Elicio Therapeutics Presents Preclinical Data on AMP TCR-T Combination Therapy in Solid Tumors at the CAR-TCR Annual Summit 2021
September 10, 2021 08:00 ET
|
Elicio Therapeutics
Data showed AMP combination with TCR-T cell therapy promotes durable responses against aggressive solid tumors in a mouse model where TCR-T cells alone have no effectAMP combination with TCR-T cell...